The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases.

Authors

Aloïs Castro, Amélie Osio, Cécile Landais, Jason Shourick, Achille Aouba, Hélène Aubert, Michèle Bernier, Sofia Bogiatzi, Gérôme Bohelay, Estelle Charvet, Marine Chastagner, Olivier Chosidow, François Comoz, Anastasia Delmotte, Marie Denis-Musquer, Vincent Descamps, Lydia Deschamps, Frédéric Dezoteux, Nicolas Dupin, Jean-François Emile, Jean-Baptiste Gibier, Chloe Grolleau, Cyril Habougit, Marie Jachiet, Marie-Laure Jullie, Jean-Emmanuel Kahn, Jean Kanitakis, Martin Killian, Guillaume Lefèvre, Cristina Bulai Livideanu, Philippe Moguelet, Nicolas Ortonne, Carle Paul, Jean Luc Perrot, Thomas Poisot, Hanta Nirina Rakotoarivelo, Julien Seneschal, Pierre Sohier, Axel P Villani, Jean-David Bouaziz, Delphine Staumont-Sallé, Maxime Battistella, François Chasset, Matthieu Groh, CEREO (French National Reference Center for Hypereosinophilic Syndromes), EMSED (Study Group of Systemic Diseases in Dermatology) networks

Published in

The journal of allergy and clinical immunology. In practice. Aug 04, 2026. Epub Aug 04, 2026.

Abstract

Eosinophilic cellulitis (EC), also known as Wells' syndrome, is a rare, poorly studied inflammatory dermatosis.
To describe the clinical and histopathological spectrum, associated conditions, outcomes of EC, and treatment response rates.
Retrospective multicenter study including patients with biopsy-proven EC. Risk factors for unfavorable clinical course (defined as recurrence or persistent disease >6 months) were assessed using univariable and multivariable logistic regression models.
A total of 114 patients (53% female, median age 52 years) were included. The most frequent clinical presentation was papulonodular (52%), with lesions predominantly on the legs (69%). Disabling pruritus was common (83%), whereas systemic symptoms were rare. Histological findings did not differ between patients with or without triggering factors or associated diseases, or between those with or without blood eosinophilia. Triggering factors and associated conditions were identified in 30 (26%) and 24 (21%) patients, respectively. Arthropod bites or stings were the most common triggering factor, whereas hematological malignancies, ANCA-negative eosinophilic granulomatosis with polyangiitis, and idiopathic hypereosinophilic syndrome were the most frequent associated conditions. Most frequently used treatments were topical (54%) and oral corticosteroids (35%), with complete response rates of 67% and 82%. Conventional synthetic DMARDs showed moderate efficacy (complete response ≤31%), whereas biologics targeting type 2 inflammation yielded promising results. In multivariable analysis, lesion size >5 cm was the only variable independently associated with unfavorable clinical course (OR 3.79 [1.42-10.10], p=0.008).
EC likely represents a disease spectrum encompassing conditions leading to eosinophil-mediated dermal toxicity. Lesion size >5 cm is associated with unfavorable clinical course. While corticosteroids achieve high remission rates, biologics targeting type 2 inflammation appear promising second-line options warranting further evaluation.

PMID:
42551694
Bibliographic data and abstract were imported from PubMed on 05 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.